57.67

1.59% 0.90

After Hours: 57.67

Crinetics Pharmaceuticals Inc (CRNX)

Overview News Price History Option Chain Financials Why CRNX Down? Discussions Forecast

Crinetics Pharmaceuticals Inc stock is traded at $57.67, with a volume of 404.39K. It is up +1.59% in the last 24 hours and down -0.50% over the past month. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Previous Close:

$56.77

Open:

$57

24h Volume:

404.39K

Relative Volume:

0.58

Market Cap:

$5.27B

Revenue:

$4.72M

Net Income/Loss:

$-258.54M

P/E Ratio:

-16.91

EPS:

-3.41

Net Cash Flow:

$-185.05M

1W Performance:

+2.85%

1M Performance:

-0.50%

6M Performance:

+21.49%

1Y Performance:

+81.30%

1-Day Range:

$56.17

$58.06

1-Week Range:

$55.30

$58.06

52-Week Range:

$30.87

$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name

Crinetics Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

858-450-6464

Address

10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA

Employee

210

Twitter

@Crinetics

Next Earnings Date

2024-11-12

Latest SEC Filings

CRNX's Discussions on Twitter

Compare CRNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRNX Crinetics Pharmaceuticals Inc	57.67	5.27B	4.72M	-258.54M	-185.05M	-3.41
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-06-24	Initiated	Citigroup	Buy
Jan-16-24	Initiated	Morgan Stanley	Overweight
Dec-21-23	Initiated	Jefferies	Hold
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-31-23	Initiated	Oppenheimer	Outperform
Apr-24-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Robert W. Baird	Outperform
Nov-30-21	Initiated	JMP Securities	Mkt Outperform
Nov-23-21	Initiated	Evercore ISI	Outperform
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-23-19	Initiated	ROTH Capital	Buy
Feb-14-19	Initiated	H.C. Wainwright	Buy
Aug-13-18	Initiated	JP Morgan	Neutral
Aug-13-18	Initiated	Leerink Partners	Outperform
Aug-13-18	Initiated	Piper Jaffray	Overweight

View All

Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News

Nov 27, 2024

Congenital Hyperinsulinism Pipeline 2024: Clinical Trials - openPR

Nov 27, 2024

Nov 25, 2024

Natixis Advisors LLC Purchases 11,870 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 25, 2024

Nov 23, 2024

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 23, 2024

Nov 22, 2024

Principal Financial Group Inc. Acquires 64,504 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 22, 2024

Nov 21, 2024

Crinetics Pharmaceuticals' SWOT analysis: biotech stock poised for growth with rich pipeline - Investing.com

Nov 21, 2024

Nov 20, 2024

Jennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 20, 2024

Victory Capital Management Inc. Has $17.55 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 20, 2024

Nov 19, 2024

First Turn Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals I - GuruFocus.com

Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Citi Global Healthcare Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals : Piper Sandler 36th Annual Healthcare Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Evercore 7th Annual HealthCONx Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Cantor Global Healthcare Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - The Manila Times

Nov 15, 2024

Crinetics Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | CRNX Stock News - StockTitan

Nov 15, 2024

EcoR1 Capital, LLC Increases Stake in Crinetics Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

HC Wainwright Has Pessimistic View of CRNX FY2024 Earnings - MarketBeat

Nov 15, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High Following Analyst Upgrade - Defense World

Nov 15, 2024

Nov 14, 2024

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline - GlobeNewswire

Nov 14, 2024

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting - The Manila Times

Nov 14, 2024

Crinetics Unveils Breakthrough Cancer Drug Platform, Reports Positive Phase 2 Trial Results | CRNX Stock News - StockTitan

Nov 14, 2024

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Yahoo Finance

Nov 14, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 14, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Nov 14, 2024

Nov 13, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat

Nov 13, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024